United Kingdom and India Announced a New Collaboration on Five New Research Projects to Tackle Antimicrobial Resistance (AMR)

Britain and India are expanding their existing scientific research collaboration with five new projects to tackle anti-microbial resistance (AMR) that could lead to important advances in the global fight against antibiotic-resistant bacteria and genes. The five projects are planned to start in September 2020. The UK is contributing £4 million from the UK Research and Innovation Fund for International Collaboration, and India is matching this with its own resources (£8 million in total). 

Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox

The development and ultimate approval of tecovirimat for the antiviral treatment of smallpox, a disease that has been eradicated from the world for nearly 40 years, required a unique regulatory approach based on the US Food and Drug Administration's Animal Rule.

Superbugs & Superdrugs

This year’s event will gather leaders from pharmaceutical companies, academia and the wider scientific community together with regulatory agencies and public-private partnerships, to discuss the growing threat of antibiotic resistance.

Setting our sights on infectious diseases

The aim of the conference is to harness cross-disciplinary and cross-disease learning to accelerate drug discovery and reduce drug candidate attrition rates for infectious diseases affecting low and middle income countries. Conference attendees will take home new ideas and technologies which have been demonstrated to work; applying them to diseases where challenges to drug discovery are hampering progress.